Shigella

LimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V

Retrieved on: 
Thursday, February 22, 2024
Research, Infectious Diseases, Hospitals, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Injection, Doctor of Philosophy, Shigellosis, Infection, Military personnel, Șaeș, Safety, Immunoglobulin G, Clinical trial, Disease, Shigella, Vaccine

LimmaTech Biologics AG announced positive interim data from its Phase I/II clinical trial evaluating Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis, an infectious disease caused by Shigella bacteria.

Key Points: 
  • LimmaTech Biologics AG announced positive interim data from its Phase I/II clinical trial evaluating Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis, an infectious disease caused by Shigella bacteria.
  • Topline data from the now completed Phase I/II trial, conducted in Kenya, are expected in the first half of 2024.
  • LimmaTech’s S4V vaccine candidate demonstrated initial safety in all age groups evaluated already in the first part of the clinical trial.
  • “These positive interim results with S4V establish the very good immunogenicity that our bioconjugate vaccine candidate can generate in nine-month-old infants, a population that needs it the most,” commented Patricia Martin, PhD, Chief Operating Officer of LimmaTech.

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

Retrieved on: 
Monday, October 9, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Partnership, Shigella, AXA, Series A round, Infection, Doctor of Philosophy, Novo Holdings A/S, GSK, Public, Vaccine, Gonorrhea, Private equity, Risk, Novo, CHF, Carbohydrate, Escherichia coli, Shigellosis, Global health, Pharmaceutical industry, Health care

The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorrhea.

Key Points: 
  • The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorrhea.
  • The company expects to announce preliminary results from the Shigella program’s ongoing Phase 2 clinical trial in the second half of 2023.
  • "Within the next decade, multiple bacterial infections will become untreatable due to antimicrobial resistance, which is already a significant burden on global health.
  • The company’s overall objective is to develop and manufacture highly effective vaccines that can stop the spread of infections caused by emerging antimicrobial resistance.

A fruit fly has landed in your wine – is it OK to drink?

Retrieved on: 
Thursday, August 31, 2023
Taste, Infection, DNA, Food, Wine, Ethanol, Human, Temperature, Fruit, Salud, Drinking, Stomach, Drosophila, Metabolism, Growth, Bacteria, Mucus, Shigella, Glass, Food preservation, Flour, Listeria, Salmonella

Rotting food is rich in germs, any of which a fly can pick up on their body and transfer to where it next lands.

Key Points: 
  • Rotting food is rich in germs, any of which a fly can pick up on their body and transfer to where it next lands.
  • The fruit fly, you realise, may have just deposited potentially lethal microbes in your wine, so you toss it in the sink and pour a fresh glass.
  • The wine the fruit fly entered was also chilled, which some food poisoning bacteria find shocks their metabolism so profoundly it stops them growing.
  • The fruit fly is unlikely to change the taste of the wine, even if there are several of them.

Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 8, 2023
Vaccine, Exercise, Advisory Committee on Immunization Practices, Immunization, OPA, Research and development, Streptococcus, University, Life, Investment, IPD, Safety, Public, Advisory Committee, Licensure, G&A, Research, National Institutes of Health, Payment Card Industry Security Standards Council, Bangladesh Technical Education Board, Stage 2, History of the University of Maryland, College Park, Data monitoring committee, Breakthrough therapy, Genetically modified bacteria, Death, PCV20, Administration, SAN, Breakthrough, Rocket launcher, Infant, Ageing, Growth, PCV, R, FDA, General Administration of Sport of China, Regulation of tobacco by the U.S. Food and Drug Administration, IND, Family, Announcement, Food, Pharmaceutical industry, Cryptocurrency, Shigella

SAN CARLOS, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the second quarter ended June 30, 2023 and provided a business update.

Key Points: 
  • “Our strong balance sheet provides a solid foundation as we advance our PCV franchise and pipeline programs.
  • The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied.
  • Clearance of the adult IND application by the FDA in the fourth quarter of 2023 following submission.
  • The June 30, 2023 amount includes the $545.3 million in net proceeds from the follow-on offering completed in April 2023.

GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine

Retrieved on: 
Thursday, July 20, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Vaccine, GSK, Antigen, Trust, Bio, Wellcome Trust, Infection, Clinical trial, Recherche et Industrie Thérapeutiques, Multimedia, Shigellosis, Doctor of Philosophy, Military personnel, Death, Acquisition, GMMA, Disease, Mortality, Bacteria, Phase, Safety, Pharmaceutical industry, Shigella

“LimmaTech Bio has remained committed to developing our Shigella vaccine candidate and this agreement with GSK has its roots in our successful ongoing partnerships with them.

Key Points: 
  • “LimmaTech Bio has remained committed to developing our Shigella vaccine candidate and this agreement with GSK has its roots in our successful ongoing partnerships with them.
  • LimmaTech Bio signed a research collaboration agreement with GSK to develop novel bioconjugate antigen-based vaccines including a monovalent Shigella vaccine in cooperation with the Wellcome Trust.
  • Following positive results from the proof-of-concept human challenge clinical trial with the monovalent Shigella vaccine, LimmaTech initiated the development of a multivalent Shigella vaccine in 2018 with a Wellcome Trust grant received by GSK for the new program.
  • LimmaTech will give this candidate vaccine the greatest chance of success, while GSK continues to use its expertise to progress another vaccine in clinical development using a GSK proprietary vaccine platform technology called GMMA.

Cabos San Lucas Faces Second Lawsuit in Shigella Outbreak, Says Lange Law Firm

Retrieved on: 
Friday, June 2, 2023
Taste, Smell, Reactive arthritis, Eating, Food, Family, Restaurant, Tobacco, Cabo San Lucas, Shigella

HOUSTON, June 2, 2023 /PRNewswire/ -- As authorities investigate a Shigella outbreak linked to the Cabos San Lucas restaurant at 1636 N. Texana, Hallettsville, Texas, 77964, a woman has filed a Shigella lawsuit against Cabos San Lucas.

Key Points: 
  • HOUSTON, June 2, 2023 /PRNewswire/ -- As authorities investigate a Shigella outbreak linked to the Cabos San Lucas restaurant at 1636 N. Texana, Hallettsville, Texas, 77964, a woman has filed a Shigella lawsuit against Cabos San Lucas.
  • She allegedly got Shigella food poisoning after eating last week at Cabos San Lucas.
  • Shigella lawyer Jory Lange is representing the woman, who is one of numerous people who allegedly got Shigella food poisoning after eating last week at the Cabos San Lucas restaurant Hallettsville, Texas.
  • This is the second Shigella lawsuit filed by Jory Lange in the Cabos San Lucas food poisoning outbreak.

Lavaca County Shigella Outbreak Investigated by Record-Breaking Houston Shigella Lawyer

Retrieved on: 
Friday, June 2, 2023
Taste, Smell, Reactive arthritis, Eating, Food, Family, Restaurant, Texas Department of State Health Services, Shigella

HOUSTON, June 2, 2023 /PRNewswire/ -- Authorities are racing to determine the source of a Shigella outbreak in Lavaca County .

Key Points: 
  • HOUSTON, June 2, 2023 /PRNewswire/ -- Authorities are racing to determine the source of a Shigella outbreak in Lavaca County .
  • Texas Department of State Health Services are testing food at the location and interviewing people who got Shigella food poisoning after eating at the location.
  • This is why it's critical that restaurants who make and sell our food, ensure the food is safe before they sell it," said Houston Shigella food poisoning lawyer Jory Lange .
  • The $10 million settlement is believed to be the largest Shigella settlement in US history on behalf of a person who developed Reactive Arthritis from Shigella food poisoning.

Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Monday, February 27, 2023
Infant, OPA, IND, Webcast, Research and development, Trial of the century, Genetically modified bacteria, Peterborough, Immunization, General counsel, Administration, PCV20, Safety, General Administration of Sport of China, Senior, Research, R, CAS (formerly Chemical Abstracts Service), Infection, Investment, Shigella, Interval (mathematics), IPD, G&A, Tolerability, Sutro, Addition, PCV, Corporation, Periodontal disease, Host, Death, Growth, Exercise, Ageing, Breakthrough therapy, Equity, FDA, Element, CMC, SAN, Conference, Immunogenicity, Cryptocurrency, Pharmaceutical industry, Vaccine, Security (finance), Fine chemical

-- Successfully Raised Approximately $805 Million in Gross Proceeds in Two Follow-On Equity Offerings in 2022; $957.9 Million in Cash, Cash Equivalents and Investments as of December 31, 2022 --

Key Points: 
  • The FDA’s decision was based on positive topline results from the Phase 1/2 proof-of-concept study of VAX-24 in adults 18-64 years of age.
  • VAX-PG: Vaxcyte nominated a final vaccine candidate for VAX-PG, its novel therapeutic vaccine designed to treat periodontal disease, in the fourth quarter of 2022 and continues to progress the program.
  • The December 31, 2022, balance includes $651.6 million in net proceeds from the Company’s underwritten public offering completed in the fourth quarter of 2022.
  • Vaxcyte will host a conference call and webcast to discuss this announcement today, February 27, 2023, at 4:30 p.m.

Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases

Retrieved on: 
Wednesday, November 30, 2022
Hospital, United Nations Development Programme, Risk, Hepatitis E, Therapy, International Vaccine Institute, Severe acute respiratory syndrome coronavirus 2, Shigella, European Medicines Agency, WHO, Infection, Omicron, United Nations, Aluminium, SCB-2019, National Medical Products Administration, Transcription-mediated amplification, PQ, Development, Public health, Salmonella, Adjuvant, Fever Dream, Chikungunya, Global health, Cholera, World Health Organization, CpG, HPV, 1018, Safety, IVI, Schistosomiasis, MD, Vaccination, 2020 European Medicines Agency cyberattack, Vaccine, Pharmaceutical industry, Clover, COVID-19, Trimer

SHANGHAI, China and SEOUL, Republic of Korea, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutics, and the International Vaccine Institute, an international nonprofit organization devoted to providing vaccines critical to global public health and based in Seoul, Korea, today announced that Clinical Infectious Diseases has published additional data from SPECTRA, a global Phase 2/3 clinical trial, that showed vaccination with SCB-2019 (CpG 1018/Alum) reduced the risk of transmitting SARS-CoV-2 infection to household members, compared to placebo participants.

Key Points: 
  • Among the 134 household contacts of infected household members who had received SCB-2019, there was one case of COVID-19; among the 250 household contacts of infected household members who were not vaccinated, there were 12 cases.
  • There were no cases of symptomatic SARS-CoV-2 infection among household contacts who were partially or fully vaccinated and where the infected household member was vaccinated with SCB-2019.
  • This indicates that SCB-2019 vaccination reduced household transmission and that vaccinated household contacts also likely benefited from the protection provided by their own vaccination.
  • The study team was blinded to the assignment of SPECTRA participants to vaccine or placebo groups.

Lemonex, IVI Exchange MOU on Joint Vaccine Development

Retrieved on: 
Thursday, November 10, 2022
COVID-19, Research, Infectious Diseases, Genetics, Biotechnology, Health, Pharmaceutical, Science, Oncology, RNA transfection, Fever Dream, Chikungunya, Vaccine, United Nations, IVI, World Health Organization, Partnership, Administration, Immunotherapy, Research, International Vaccine Institute, Organization, Korea, Epidemiology, Technology, WHO, HPV, United Nations Development Programme, COVID-19, Global health, Cholera, Hepatitis E, RNA, LNP, Goal, Infection, Sirna, Shigella, Schistosomiasis, Public health, CEO, World, Salmonella, PQ, MOU, Pharmaceutical industry

The International Vaccine Institute (IVI) announced on November 10th it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy development, and agreed to seek cooperation in research and development.

Key Points: 
  • The International Vaccine Institute (IVI) announced on November 10th it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy development, and agreed to seek cooperation in research and development.
  • IVI and Lemonex have agreed to join forces to introduce DegradaBALL drug delivery technology to the development of infectious disease vaccines and advance vaccine development by using IVIs extensive expertise in all areas of vaccine development.
  • The two organizations plan to utilize Lemonex's expertise in vaccine development and drug delivery platform, and rapidly develop a safe and effective mRNA vaccine through mutual cooperation by using IVI's extensive experience in clinical development and epidemiology.
  • Cheolhee Won, CEO of Lemonex, said, We are proud to have established a vaccine R&D partnership with IVI to develop an mRNA vaccine.